Clinical trial
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced…
NCT00201825 · Tony Bekaii-Saab, Other · Completed
Key facts
| NCT number | NCT00201825 |
|---|---|
| Title | A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients |
| Official title | A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients |
| Lead sponsor | Tony Bekaii-Saab, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Capecitabine, Docetaxel |
| Enrollment | 29 |
| Start date | Dec 1, 2004 |
| Primary completion | Dec 1, 2012 |
| Completion | Apr 1, 2013 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: